Details of Disease

Disease Name

Bladder transitional cell carcinoma

BLCA; urothelial carcinoma of the urinary bladder; transitional cell carcinoma of the urinary bladder; bladder transitional cell carcinoma; transitional cell carcinoma of bladder; urinary bladder transitional cell carcinoma; urinary bladder urothelial carcinoma; bladder urothelial carcinoma; bladder urothelial cancer; urothelial bladder carcinoma

Definition

The most common morphologic subtype of urinary bladder carcinoma (over 90% of cases). It arises from the transitional epithelium. It most often affects males in their sixth and seventh decades of life. Hematuria is the most common symptom at presentation. Pathologic stage is the strongest predictor of survival.

Disease Hierarchy

DISWVVDR: Transitional cell carcinoma

DISUHNM0: Bladder cancer

DISRTNTN: Urothelial carcinoma

DISNL46A: Bladder transitional cell carcinoma

Disease Identifiers

MONDO ID

MONDO_0005611

UMLS CUI

C0279680

MedGen ID

76013

HPO ID

HP:0006740

SNOMED CT ID

255109008

General Information of Disease (ID: DISNL46A)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 27 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MAPK1	TT4TQBX	Limited	Altered Expression	[1]
PAX5	TTA4REJ	Limited	Altered Expression	[2]
SLC12A5	TTH6UZY	Limited	Altered Expression	[3]
PRSS8	TTT4N0Q	Disputed	Biomarker	[4]
KRAS	TTM8FR7	moderate	Genetic Variation	[5]
CREBBP	TTFRCTK	Strong	Genetic Variation	[6]
EP300	TTGH73N	Strong	Genetic Variation	[6]
ERBB2	TTR5TV4	Strong	Altered Expression	[7]
ERBB3	TTSINU2	Strong	Genetic Variation	[6]
FBXW7	TT29KY7	Strong	Genetic Variation	[6]
FOXQ1	TTEJZOL	Strong	Biomarker	[8]
FUT4	TTNV1KZ	Strong	Altered Expression	[9]
IDH1	TTV2A1R	Strong	Genetic Variation	[6]
MAP2K1	TTIDAPM	Strong	Genetic Variation	[6]
NEDD9	TT1UREA	Strong	Altered Expression	[10]
NME1	TTDY8JH	Strong	Biomarker	[11]
NRAS	TTW2R9X	Strong	Genetic Variation	[6]
PSEN2	TTWN3F4	Strong	Altered Expression	[12]
RXRA	TT6PEUO	Strong	Genetic Variation	[6]
SF3B1	TTL2WUI	Strong	Genetic Variation	[6]
ADORA2B	TTNE7KG	Definitive	Biomarker	[13]
DDIT4	TTVEOY6	Definitive	Biomarker	[14]
DDR2	TTU98HG	Definitive	Altered Expression	[15]
HTATIP2	TTC6IX5	Definitive	Altered Expression	[16]
PINX1	TT4FJ3A	Definitive	Biomarker	[17]
RIPK4	TTB4S01	Definitive	Biomarker	[18]
RSF1	TTMP86V	Definitive	Altered Expression	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 27 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A10	DTPAQJO	moderate	Biomarker	[2]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP4B1	DEMF740	moderate	Altered Expression	[20]
GSTO2	DEHMPZR	moderate	Genetic Variation	[21]
CYB5R3	DE4A3BL	Strong	Biomarker	[22]
------------------------------------------------------------------------------------

This Disease Is Related to 48 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CD8A	OTDWQJXK	Limited	Genetic Variation	[23]
COMMD10	OT1ANQLQ	Limited	Biomarker	[24]
ERH	OTJDWX99	Limited	Biomarker	[25]
HHLA2	OTYBTVQS	Limited	Altered Expression	[26]
RB1	OT9VMY7B	Limited	Genetic Variation	[27]
KCNH4	OTHJ8WTU	Disputed	Altered Expression	[28]
MZF1	OTMVZCPW	Disputed	Altered Expression	[28]
NR2F1	OTGWZWYL	Disputed	Altered Expression	[29]
RFXANK	OTDX1026	Disputed	Genetic Variation	[30]
FSIP1	OTYLL6GM	moderate	Altered Expression	[31]
HMGN5	OTUUAHVQ	moderate	Altered Expression	[32]
KRT20	OT4RB40L	moderate	Biomarker	[33]
RBM5	OTCBWHHV	moderate	Altered Expression	[34]
SLC26A8	OTNCW8RJ	moderate	Biomarker	[2]
SPAG5	OTCLJ56M	moderate	Biomarker	[35]
ARID1B	OTILK3Q7	Strong	Altered Expression	[36]
CEBPD	OTNBIPMY	Strong	Altered Expression	[37]
CEP55	OTGSG2PA	Strong	Biomarker	[38]
CEP72	OTVYNPNL	Strong	Altered Expression	[39]
CLASP2	OT5YX0YB	Strong	Altered Expression	[40]
CNOT9	OT1NIIQD	Strong	Genetic Variation	[6]
HSPA2	OTSDET7B	Strong	Biomarker	[41]
NEU1	OTH9BY8Y	Strong	Altered Expression	[42]
NEURL1	OT2C4P70	Strong	Altered Expression	[42]
OPCML	OT93PQ6Y	Strong	Biomarker	[43]
RHEB	OTFLTSEC	Strong	Genetic Variation	[6]
SPAG9	OT45AHMB	Strong	Altered Expression	[10]
ACTR2	OT3C8U5T	Definitive	Altered Expression	[44]
ADGRB1	OTJSEXRC	Definitive	Biomarker	[45]
AHNAK	OT6KH1WG	Definitive	Biomarker	[46]
ANLN	OTXJY54C	Definitive	Altered Expression	[47]
ELAVL3	OTI2VI8B	Definitive	Altered Expression	[48]
EMP2	OTPS2H0L	Definitive	Altered Expression	[49]
FLOT1	OT0JPPJZ	Definitive	Altered Expression	[50]
KCNH8	OT3I5FLB	Definitive	Altered Expression	[28]
MCM5	OTAHLB62	Definitive	Altered Expression	[51]
MED19	OTT9RT5N	Definitive	Biomarker	[52]
MEX3A	OTB0OEQN	Definitive	Altered Expression	[53]
NCKIPSD	OT24UORN	Definitive	Biomarker	[54]
PCDH17	OTRK0M05	Definitive	Posttranslational Modification	[55]
PLAGL2	OT6AP4V2	Definitive	Altered Expression	[56]
PLCL1	OTJL2C79	Definitive	Biomarker	[57]
POLD2	OTBNASP6	Definitive	Altered Expression	[58]
RBX1	OTYA1UIO	Definitive	Biomarker	[59]
RIN1	OTPBROUD	Definitive	Altered Expression	[60]
SEPTIN4	OTD16B30	Definitive	Altered Expression	[61]
SULF1	OTJCNCO0	Definitive	Altered Expression	[62]
TRIM65	OTSQTK3A	Definitive	Biomarker	[63]
------------------------------------------------------------------------------------


⏷ Show the Full List of 48 DOT(s)

References

1	The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma.J Oncol. 2017;2017:6095205. doi: 10.1155/2017/6095205. Epub 2017 Jan 17.
2	Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder.Urology. 2006 Apr;67(4):756-61. doi: 10.1016/j.urology.2005.10.053. Epub 2006 Mar 29.
3	Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-B/MMP-7 signaling pathway.Cell Death Dis. 2017 Mar 23;8(3):e2691. doi: 10.1038/cddis.2017.118.
4	Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT).BMC Cancer. 2009 Oct 22;9:377. doi: 10.1186/1471-2407-9-377.
5	Bladder Urothelial Carcinoma in a Child: Case Report and Review of Literature.Front Pediatr. 2019 Sep 20;7:385. doi: 10.3389/fped.2019.00385. eCollection 2019.
6	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
7	Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.Med Sci Monit. 2018 Oct 8;24:7178-7185. doi: 10.12659/MSM.911640.
8	LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC).Am J Cancer Res. 2018 Apr 1;8(4):748-760. eCollection 2018.
9	Clinicopathological implications to micropapillary bladder urothelial carcinoma of the presence of sialyl Lewis X-decorated mucin 1 in stroma-facing membranes.Urol Oncol. 2017 Oct;35(10):606.e17-606.e23. doi: 10.1016/j.urolonc.2017.06.004. Epub 2017 Jun 27.
10	SPAG9 regulates HEF1 expression and drives EMT in bladder transitional cell carcinoma via rac1 signaling pathway.Am J Cancer Res. 2018 Dec 1;8(12):2467-2480. eCollection 2018.
11	The role of nm23-H1 in the progression of transitional cell bladder cancer.Clin Cancer Res. 2000 Sep;6(9):3595-9.
12	Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas.Eur Urol. 2001 Aug;40(2):163-8. doi: 10.1159/000049767.
13	The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway.Oncotarget. 2017 Jul 25;8(30):48755-48768. doi: 10.18632/oncotarget.17835.
14	Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy.Clin Cancer Res. 2018 Jan 15;24(2):445-459. doi: 10.1158/1078-0432.CCR-17-0419. Epub 2017 Oct 30.
15	DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.Oncotarget. 2016 Nov 29;7(48):78918-78931. doi: 10.18632/oncotarget.12912.
16	Reduction of Tat-interacting Protein 30 Expression Could be a Prognostic Marker in Bladder Urothelial Cancer.Chin Med J (Engl). 2018 Jan 20;131(2):188-193. doi: 10.4103/0366-6999.222325.
17	PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.Mol Cancer. 2013 Nov 23;12(1):148. doi: 10.1186/1476-4598-12-148.
18	RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-B pathway.Br J Cancer. 2018 Jun;118(12):1617-1627. doi: 10.1038/s41416-018-0116-8. Epub 2018 Jun 5.
19	Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.
20	Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.APMIS. 2019 Apr;127(4):170-180. doi: 10.1111/apm.12939.
21	GSTO1C/GSTO2G haplotype is associated with risk of transitional cell carcinoma of urinary bladder.Int Urol Nephrol. 2015 Apr;47(4):625-30. doi: 10.1007/s11255-015-0933-0. Epub 2015 Feb 26.
22	Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.Clin Cancer Res. 2002 Apr;8(4):1258-70.
23	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.Theranostics. 2017 Aug 22;7(14):3585-3594. doi: 10.7150/thno.21471. eCollection 2017.
24	Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human.Cancer Gene Ther. 2020 Apr;27(3-4):216-225. doi: 10.1038/s41417-019-0087-9. Epub 2019 Feb 21.
25	The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells.BMC Cancer. 2019 Mar 12;19(1):225. doi: 10.1186/s12885-019-5423-9.
26	Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.Nephron. 2019;141(4):256-264. doi: 10.1159/000495887. Epub 2019 Jan 2.
27	Expression of bcl-2 and bcl-X in bladder cancer.J Urol. 1998 Apr;159(4):1348-53.
28	Expression of protein kinase C and the MZF-1 and elk-1 transcription factors in human bladder transitional cell carcinoma cells.Chin J Physiol. 2012 Apr 30;55(2):75-81. doi: 10.4077/CJP.2012.AMM121.
29	Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.Urology. 2008 Oct;72(4):921-6. doi: 10.1016/j.urology.2008.02.019. Epub 2008 Apr 2.
30	Characterization of genes associated with different phenotypes of human bladder cancer cells.Acta Biochim Biophys Sin (Shanghai). 2006 Sep;38(9):602-10. doi: 10.1111/j.1745-7270.2006.00205.x.
31	Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.Onco Targets Ther. 2018 Apr 5;11:1961-1971. doi: 10.2147/OTT.S158275. eCollection 2018.
32	HMGN5 expression in bladder cancer tissue and its role on prognosis.Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):970-975. doi: 10.26355/eurrev_201802_14378.
33	Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2.
34	Down-regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR-432-5p/-catenin feedback loop.FASEB J. 2019 Oct;33(10):10973-10985. doi: 10.1096/fj.201900537R. Epub 2019 Jul 18.
35	SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.J Hematol Oncol. 2019 Feb 8;12(1):14. doi: 10.1186/s13045-019-0700-2.
36	Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma.J Cancer. 2017 Sep 27;8(17):3490-3497. doi: 10.7150/jca.19109. eCollection 2017.
37	Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.Clin Cancer Res. 2017 Jan 15;23(2):503-513. doi: 10.1158/1078-0432.CCR-15-1169. Epub 2016 Jul 19.
38	Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.Immunobiology. 2015 Jan;220(1):103-8. doi: 10.1016/j.imbio.2014.08.014. Epub 2014 Aug 21.
39	Overexpression of CEP72 Promotes Bladder Urothelial Carcinoma Cell Aggressiveness via Epigenetic CREB-Mediated Induction of SERPINE1.Am J Pathol. 2019 Jun;189(6):1284-1297. doi: 10.1016/j.ajpath.2019.02.014. Epub 2019 Apr 4.
40	Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: A propensity score-based analysis.Urol Oncol. 2019 Oct;37(10):800-807. doi: 10.1016/j.urolonc.2019.05.003. Epub 2019 May 24.
41	Heat shock protein 70-2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth.BMC Cancer. 2016 Jul 29;16:561. doi: 10.1186/s12885-016-2592-7.
42	HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?.Eur J Cancer. 2004 Jan;40(1):56-63. doi: 10.1016/j.ejca.2003.08.027.
43	Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.Eur J Cancer. 2011 May;47(7):1106-14. doi: 10.1016/j.ejca.2010.12.025. Epub 2011 Jan 25.
44	Upregulation of Arp2 expression is associated with the prognosis and prediction of lymph node metastasis in bladder urothelial carcinoma.Cancer Manag Res. 2018 Mar 19;10:503-511. doi: 10.2147/CMAR.S155453. eCollection 2018.
45	Expression of brainspecific angiogenesis inhibitor? and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma.Mol Med Rep. 2015 Sep;12(3):4522-4529. doi: 10.3892/mmr.2015.3984. Epub 2015 Jun 23.
46	Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.Mol Cell Proteomics. 2018 Sep;17(9):1788-1802. doi: 10.1074/mcp.RA118.000562. Epub 2018 Jun 27.
47	Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma.Sci Rep. 2017 Jun 9;7(1):3151. doi: 10.1038/s41598-017-02990-9.
48	Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma.Cancer Chemother Pharmacol. 2016 Mar;77(3):507-13. doi: 10.1007/s00280-016-2964-3. Epub 2016 Jan 19.
49	The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma.Oncotarget. 2015 Apr 20;6(11):9220-39. doi: 10.18632/oncotarget.3312.
50	Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma.Oncol Rep. 2014 Aug;32(2):748-54. doi: 10.3892/or.2014.3221. Epub 2014 May 29.
51	Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.Cytopathology. 2019 Sep;30(5):510-518. doi: 10.1111/cyt.12698. Epub 2019 May 20.
52	Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2.Ann Diagn Pathol. 2013 Jun;17(3):259-64. doi: 10.1016/j.anndiagpath.2012.11.004. Epub 2012 Dec 29.
53	Mex3a expression and survival analysis of bladder urothelial carcinoma.Oncotarget. 2017 Jun 7;8(33):54764-54774. doi: 10.18632/oncotarget.18399. eCollection 2017 Aug 15.
54	LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression.Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):143-151. doi: 10.21873/cgp.20072.
55	Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.J Int Med Res. 2014 Apr;42(2):292-9. doi: 10.1177/0300060513504364. Epub 2014 Feb 24.
56	Expression of PLAGL2 in bladder urothelial carcinoma and its relationship to lymph node metastasis and survival.Sci Rep. 2018 Apr 16;8(1):6044. doi: 10.1038/s41598-018-24526-5.
57	Knockdown of PLC inhibits inflammatory cytokine release via STAT3 phosphorylation in human bladder cancer cells.Tumour Biol. 2015 Dec;36(12):9723-32. doi: 10.1007/s13277-015-3712-8. Epub 2015 Jul 9.
58	CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma.Oncotarget. 2018 Jul 3;9(51):29743-29752. doi: 10.18632/oncotarget.25701. eCollection 2018 Jul 3.
59	Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence.PLoS One. 2013 May 8;8(5):e62734. doi: 10.1371/journal.pone.0062734. Print 2013.
60	Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma.Tumour Biol. 2012 Jun;33(3):847-55. doi: 10.1007/s13277-011-0311-1. Epub 2012 Jan 17.
61	Bradeion (SEPT4) as a urinary marker of transitional cell bladder cancer: a real-time polymerase chain reaction study of gene expression.J Urol. 2012 Jun;187(6):2223-7. doi: 10.1016/j.juro.2012.01.031. Epub 2012 Apr 13.
62	Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.Oncotarget. 2017 Jul 18;8(29):47216-47229. doi: 10.18632/oncotarget.17590.
63	TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation.Cancer Lett. 2018 Oct 28;435:10-22. doi: 10.1016/j.canlet.2018.07.036. Epub 2018 Aug 1.